Clinical Trial Search

Primary: Change in Mean Sitting Systolic Blood Pressure (msSBP) From Baseline to Week 8 — -8.01; -6.30 mmHg

Primary: Change in Total PANSS (Positive and Negative Syndrome Scale)Score From Baseline to the End of the Double Blind Treatment Period. — -25.7; -23.6; -28.7; -16.0 Units on a…

Primary: Antimicrobial Species in Plaque(Actinomyces) — 0.023; 0.3881; 0.0538 log CFU (Colony forming units) — p=0.05

Primary: Number of Participants With Recurrent Symptomatic Venous Thromboembolism (VTE) and Deaths Related to VTE — 30; 27; 34; 32 Participants — p=<0.0001

Primary: Percent of Participants With Disease Flare in Part II (After 24 Weeks of the Double-blind Part) — 0; 81.3 percent of participants

Primary: Percentage of Participants Who Experienced Adverse Events — 83.93; 83.93 percentage of participants

Primary: Mean Percent Change of Forced Expiratory Volume in One Second (FEV1) From Baseline to Week 12. — -1.09; -0.02 Percent Change of FEV1 — p=0.4982

Primary: Yearly Event Rate for Composite Endpoint of Stroke/SEE — 1.54; 1.11; 1.71 yearly event rate (percentage) — p=<.0001

Primary: Number of Subjects With Booster Responses to Diphteria and Tetanus — 209; 207; 208; 203 Participants

Primary: Time to Progression (TTP) — 10.8; 10.2 months

Primary: Percentage of Participants With Suppression of Peak Stimulated Luteinizing Hormone (<4 mIU/mL) From Month 2 Through Month 6 — 76.2; 80.7; 90.5; 100 Percentage of…

Primary: Change in Mean Sitting Diastolic Blood Pressure (msDBP) From Baseline to End of Study (Week 8) — -9.7; -7.1 mmHg

Primary: Number of Patients With Detrusor Leak Point Pressure (LPP) < 40 cm H2O — 23; 23; 28; 34 participants — p=1.00

Primary: Investigator Hemostatic Efficacy Assessment 8 Hours Post Infusion — 1.86 Units on a scale

Primary: Number of Participants With a Decrease From Baseline ≥ 1 in the Society of Fetal Urology (SFU) Grade of Hydronephrosis — 2; 5; 3; 1 participants